Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?

[1]  F. Broccolo,et al.  Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role? , 2022, Clinical chemistry and laboratory medicine.

[2]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[3]  G. Lippi,et al.  Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants , 2021, Clinical chemistry and laboratory medicine.

[4]  A. C. Simões e Silva,et al.  The impact of Vaccination worldwide on SARS-CoV-2 infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants. , 2021, Current medicinal chemistry.

[5]  M. Pai,et al.  COVID-19 boosters in rich nations will delay vaccines for all. , 2021, Nature medicine.

[6]  L. Heylen,et al.  Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. , 2021, JAMA.

[7]  Aaron M. Rosenfeld,et al.  mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern , 2021, bioRxiv.

[8]  F. Mullier,et al.  Post-SARS-CoV-2 vaccination specific antibody decrease — Thresholds for determining seroprevalence and seroneutralization differ , 2021, Journal of Infection.

[9]  Lindsay N. Carpp,et al.  Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial , 2021, medRxiv.

[10]  R. A. Kaiser,et al.  Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients , 2021, Kidney International.

[11]  F. Rey,et al.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[12]  J. Vekemans,et al.  Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[13]  N. Allen,et al.  Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals , 2021, Infectious Diseases and Therapy.

[14]  G. Lippi,et al.  Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How? , 2021, Diagnostics.

[15]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[16]  R. Kučera,et al.  Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test , 2021, Diagnostics.

[17]  C. Giaquinto,et al.  Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers , 2021, Clinical chemistry and laboratory medicine.

[18]  G. Lippi,et al.  Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination , 2021, Clinical chemistry and laboratory medicine.

[19]  A. Sette,et al.  Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[21]  M. V. von Herrath,et al.  Faculty Opinions recommendation of Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[22]  N. Smith,et al.  COVID-19: in the absence of vaccination – ‘mask-the-nation’ , 2020, Future microbiology.

[23]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.